ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Samsung Bioepis and Astellas Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Samsung BioepisAstellas Pharma
studies on the registry33983
open to participants now238
phase 3 studies under way113
reach primary completion within a year114
programswith a study of their own in two years420

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSamsung BioepisAstellas Pharma
Phase 1

Samsung Bioepis: 2 of its 4 programs at phase 1

  1. ixekizumabphase 1
  2. potassium L-ascorbatephase 1
50%

Astellas Pharma: 2 of its 20 programs at phase 1

  1. ASP2020phase 1
  2. Pan-KRAS Degrader ASP5834phase 1
10%
Phase 2

Samsung Bioepis: 2 of its 4 programs at phase 2

  1. Ranibizumabphase 2
  2. afliberceptphase 2
50%
45%
Phase 300%

Astellas Pharma: 4 of its 20 programs at phase 3

  1. fezolinetantphase 3
  2. setidegrasibphase 3
  3. emaretamigphase 3
  4. gilteritinibphase 3
20%
Approved, new studies00%

Astellas Pharma: 5 of its 20 programs at approved, new studies

  1. zolbetuximabapproved, new study
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study
  4. avacincaptad pegolapproved, new study
  5. Sirolimusapproved, new study
25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Samsung Bioepis1 readouts · 0 phase 3·······

Samsung Bioepis, Jun ’27: 1 program whose next study reaches primary completion

  1. ixekizumabphase 1 · Jun 9 · NCT07789964
····
Astellas Pharma9 readouts · 2 phase 3·

Astellas Pharma, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Cphase 2 · Dec 30 · NCT06792435
  2. enfortumab vedotinapproved, new study · Dec 31 · NCT06862219
  3. zolbetuximabapproved, new study · Dec 31 · NCT06396091
···

Astellas Pharma, Apr ’27: 2 programs whose next study reaches primary completion

  1. enzalutamideapproved, new study · Apr 30 · NCT07783282
  2. fezolinetantphase 3 · Apr 30 · NCT07783282
·

Astellas Pharma, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. avacincaptad pegolapproved, new study · Jun 30 · NCT06970665
···

Astellas Pharma, Oct ’27: 3 programs whose next study reaches primary completion

  1. Methylprednisolonephase 2 · Oct 31 · NCT07052929
  2. Prednisolonephase 2 · Oct 31 · NCT07052929
  3. Sirolimusapproved, new study · Oct 31 · NCT07052929
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Samsung Bioepis

New programs 1

  • afliberceptphase 2 · first study · Sep 21 · Macular Degeneration

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Astellas Pharma

New programs 1

  • ASP2957phase 2 · first study · Oct 9 · Myopathies, Structural, Congenital

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionSamsung BioepisAstellas Pharma
Macular Degenerationboth · compare here

Samsung Bioepis in Macular Degeneration: 2 programs

  1. Ranibizumabphase 2
  2. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Macular Degeneration in search

Astellas Pharma in Macular Degeneration: 1 program

  1. avacincaptad pegolapproved, new study

Their studies: Astellas Pharma’s studies of Macular Degeneration in search

Arthritis, Rheumatoidboth · compare here

Samsung Bioepis in Arthritis, Rheumatoid: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Arthritis, Rheumatoid in search

Astellas Pharma in Arthritis, Rheumatoid: 1 program

  1. Prednisolonephase 2

Their studies: Astellas Pharma’s studies of Arthritis, Rheumatoid in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Samsung Bioepis 3 of 4 · Astellas Pharma 12 of 20 programs (14 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.